Legislation
-
SAHPRA registers new long-acting HIV pre-exposure prophylaxis
South Africa has just approved Apretude, the first long-acting injectable to help prevent HIV infection. This breakthrough offers a highly effective, convenient option for those at higher risk—marking a turning point in local HIV prevention efforts. Read more about what this means for public health.
-
SAHPRA concludes backlog clearance project
SAHPRA has successfully cleared a years-long backlog of over 16,000 medicine applications, unlocking faster access to essential therapies in South Africa. Discover how this milestone marks a new era for safe, affordable healthcare and regulatory efficiency.
-
How voluntary licensing is increasing access to medicine
Discover how voluntary licensing is helping millions access affordable, life-saving HIV medicines worldwide. As we mark World AIDS Day, find out how new partnerships are making a difference for patients who need it most.
-
Fortigel obtains health claim approval in Brazil
Fortigel by Gelita is now the first type I collagen to receive official approval from Brazil’s health agency, allowing joint health claims on supplement labels. Supported by robust scientific studies, Fortigel may help maintain normal joint function and mobility—discover what sets this patented collagen apart.
-
MDMSA announces independence to improve med tech sector in SA
MDMSA’s independence marks a new chapter for South Africa’s med-tech manufacturers, unlocking access to key government partnerships, export opportunities, and funding support for global certifications. Discover how this move will strengthen local industry growth and drive international competitiveness.
-
CTFA now a registered entity
The Cosmetic Toiletry & Fragrance Association of South Africa (CTFA) is now fully registered, boosting its credibility and commitment to the industry. Discover what this milestone means for local cosmetic businesses and how it strengthens support for members—read more about the impact of this important development.
-
SAHPRA clarifies process for importation of medicines
SAHPRA clarifies how healthcare professionals can access unregistered oncology medicines when needed for patients, and addresses recent questions raised by the media. Learn how the Section 21 process works to ensure responsible, case-by-case access to essential treatments in South Africa.
-
SAHPRA approves breakthrough granule treatment for children with HIV
SAHPRA has approved a new, sweet-tasting HIV granule treatment for young children, making medicine easier and safer to give. Discover how this breakthrough and other newly registered child-friendly HIV options could transform care for South African families.
-
Iberchem launches biodegradable fragrance encapsulation technology
Discover Iberchem’s Vernovacaps—the first fragrance capsules to meet strict OECD biodegradability standards. Designed for fabric softeners and soon personal care, this breakthrough technology leads the way in sustainable scent solutions. Find out how Iberchem’s innovation can boost your green portfolio.
-
Medical law reformation in SA could be life-saving for cancer patients
Major changes in South African medical law could make breakthrough cancer treatments affordable and accessible to more patients. Discover how reforming medicine pricing might help save thousands of lives in the face of our country’s rising cancer crisis.
-
SAHPRA registers two COVID-19 vaccines
SAHPRA has officially registered two COVID-19 vaccines—Pfizer’s COMIRNATY and MC Pharma’s vaccine—marking a new chapter in South Africa’s pandemic response. Find out what this means for vaccine rollout and public health in the country.
-
GESlabs licenced by SAHPRA to produce cannabinoid pharma ingredients
GESLabs has secured SAHPRA approval to manufacture pharmaceutical-grade cannabinoid ingredients at its new Cape Town facility, backed by R20 million in foreign investment. Discover how this world-class lab is setting new benchmarks for South Africa’s medical innovation and global export.
